AML (N-Act) AI
Acute Myeloid Leukemia
Key Facts
About Biostate AI
Biostate AI is a global, integrated biotechnology company building a full-stack platform for precision health, spanning from proprietary wet lab sequencing technologies to autonomous AI scientific research. The company has established a significant international footprint through subsidiaries and joint ventures in the US, China, India, and Saudi Arabia, focusing on generating high-fidelity genomic data at reduced cost and translating it into actionable clinical insights. Led by a team with strong academic and commercial backgrounds, including a CEO with a track record of venture fundraising and revenue generation, Biostate appears to be in an early-revenue stage, leveraging its platform for both internal programs and external collaborations. Its strategy hinges on scaling data generation and applying AI to enable proactive, predictive healthcare.
View full company profileOther Acute Myeloid Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| AFM28 | Affimed | Phase 1/2 |
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| QL325 | QLSF Biotherapeutics | Phase 1 |
| NPM1 Testing in AML | Diatech Pharmacogenetics | Commercial |
| Joint Development for AML | Ordaos Bio | Pre-clinical |
| RG6356 (RO7434656) | Chugai Pharmaceutical | Phase III |
| AL8326 | Shanghai Allist Pharmaceuticals | Phase II |